Editorial: Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases [Editorial]: Where do we stand? Volume II (2022)
- Authors:
- USP affiliated authors: FARIAS, KELEN CRISTINA RIBEIRO MALMEGRIM DE - FCFRP ; RODRIGUES, MARIA CAROLINA DE OLIVEIRA - FMRP
- Unidades: FCFRP; FMRP
- DOI: 10.3389/fimmu.2022.1038338
- Subjects: DOENÇAS AUTOIMUNES; TRANSPLANTE AUTÓLOGO; CÉLULAS-TRONCO; ESCLEROSE MÚLTIPLA
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Frontiers in Immunology
- ISSN: 1664-3224
- Volume/Número/Paginação/Ano: v. 13, art. 1038338, p. 1-3, 2022
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by
-
ABNT
MALMEGRIM, Kelen Cristina Ribeiro et al. Editorial: Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases [Editorial]: Where do we stand? Volume II. Frontiers in Immunology. Lausanne: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.3389/fimmu.2022.1038338. Acesso em: 19 abr. 2024. , 2022 -
APA
Malmegrim, K. C. R., Toubert, A., Farge, D., & Rodrigues, M. C. de O. (2022). Editorial: Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases [Editorial]: Where do we stand? Volume II. Frontiers in Immunology. Lausanne: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. doi:10.3389/fimmu.2022.1038338 -
NLM
Malmegrim KCR, Toubert A, Farge D, Rodrigues MC de O. Editorial: Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases [Editorial]: Where do we stand? Volume II [Internet]. Frontiers in Immunology. 2022 ; 13 1-3.[citado 2024 abr. 19 ] Available from: https://doi.org/10.3389/fimmu.2022.1038338 -
Vancouver
Malmegrim KCR, Toubert A, Farge D, Rodrigues MC de O. Editorial: Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases [Editorial]: Where do we stand? Volume II [Internet]. Frontiers in Immunology. 2022 ; 13 1-3.[citado 2024 abr. 19 ] Available from: https://doi.org/10.3389/fimmu.2022.1038338 - Editorial: immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases: where do we stand?
- New horizons in the treatment of type 1 diabetes: more intense immunosuppression and beta cell replacement
- Teplizumab in relatives at risk for type 1 diabetes. [Carta]
- Lower Insulin-Dose Adjusted A1c (IDAA1c) is associated with less complications in individuals with type 1 diabetes treated with hematopoetic stem-cell transplantation and conventional therapy
- Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases [Editorial]: where do we stand?
- Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases: where do we stand?
- New horizons in the treatment of type 1 diabetes: more intense immunosuppression and beta cell replacement
- CMV-specific clones may lead to reduced TCR diversity and relapse in systemic sclerosis patients treated with AHSCT [Carta]
- Autologous hematopoietic stem cell transplantation for autoimmune diseases: from mechanistic insights to biomarkers
- Transplante de células-tronco hematopoéticas para doenças auto-imunes graves e refratárias ao tratamento convencional
Informações sobre o DOI: 10.3389/fimmu.2022.1038338 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
